Seasonal influenza split vaccines confer partial cross-protection against heterologous influenza virus in ferrets when combined with the CAF01 adjuvant by Christensen, Dennis et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Seasonal influenza split vaccines confer partial cross-protection against heterologous
influenza virus in ferrets when combined with the CAF01 adjuvant
Christensen, Dennis; Christensen, Jan P.; Korsholm, Karen S.; Isling, Louise K.; Erneholm,
Karin; Thomsen, Allan R.; Andersen, Peter
Published in:
Frontiers in Immunology
DOI:
10.3389/fimmu.2017.01928
Publication date:
2018
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Christensen, D., Christensen, J. P., Korsholm, K. S., Isling, L. K., Erneholm, K., Thomsen, A. R., & Andersen, P.
(2018). Seasonal influenza split vaccines confer partial cross-protection against heterologous influenza virus in
ferrets when combined with the CAF01 adjuvant. Frontiers in Immunology, 8, [1928].
https://doi.org/10.3389/fimmu.2017.01928
Download date: 03. Feb. 2020
January 2018 | Volume 8 | Article 19281
Original research
published: 08 January 2018
doi: 10.3389/fimmu.2017.01928
Frontiers in Immunology | www.frontiersin.org
Edited by: 
Ken J. Ishii, 
National Institutes of Biomedical 
Innovation, Health and Nutrition, 
Japan
Reviewed by: 
Ali Ellebedy, 
Washington University in St. Louis, 
United States  
Rino Rappuoli, 
GlaxoSmithKline, Italy  
Michael Schotsaert, 
Icahn School of Medicine at Mount 
Sinai, United States
*Correspondence:
Dennis Christensen  
den@ssi.dk
†Present address: 
Karin Erneholm, 
Timeline Bioresearch, Lund, Sweden
‡These authors have contributed 
equally to this work.
Specialty section: 
This article was submitted to 
Vaccines and Molecular 
Therapeutics, 
a section of the journal 
Frontiers in Immunology
Received: 15 September 2017
Accepted: 15 December 2017
Published: 08 January 2018
Citation: 
Christensen D, Christensen JP, 
Korsholm KS, Isling LK, Erneholm K, 
Thomsen AR and Andersen P (2018) 
Seasonal Influenza Split Vaccines 
Confer Partial Cross-Protection 
against Heterologous Influenza 
Virus in Ferrets When Combined 
with the CAF01 Adjuvant. 
Front. Immunol. 8:1928. 
doi: 10.3389/fimmu.2017.01928
seasonal influenza split Vaccines 
confer Partial cross-Protection 
against heterologous influenza Virus 
in Ferrets When combined with the 
caF01 adjuvant
Dennis Christensen1*‡, Jan P. Christensen2‡, Karen S. Korsholm1, Louise K. Isling3,  
Karin Erneholm1†, Allan R. Thomsen2 and Peter Andersen1
1 Department of Infectious Disease Immunology, Division of Vaccine, Statens Serum Institut, Copenhagen, Denmark, 
2 Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark, 3 Department of Quality 
Assurance/Quality Control, Section of Biological Service, Division of Vaccine, Statens Serum Institut, Copenhagen, Denmark
Influenza epidemics occur annually, and estimated 5–10% of the adult population and 
20–30% of children will become ill from influenza infection. Seasonal vaccines primarily 
work through the induction of neutralizing antibodies against the principal surface antigen 
hemagglutinin (HA). This important role of HA-specific antibodies explains why previous 
pandemics have emerged when new HAs have appeared in circulating human viruses. 
It has long been recognized that influenza virus-specific CD4(+) T cells are important 
in protection from infection through direct effector mechanisms or by providing help to 
B cells and CD8(+) T cells. However, the seasonal influenza vaccine is poor at inducing 
CD4(+) T-cell responses and needs to be combined with an adjuvant facilitating this 
response. In this study, we applied the ferret model to investigate the cross-protective 
efficacy of a heterologous trivalent influenza split-virion (TIV) vaccine adjuvanted with the 
CAF01 adjuvant, with proven ability to induce CD4(+) T-cell and antibody responses in 
mice, ferrets, pigs, primates, and humans. Our results indicate that CAF01-adjuvanted 
vaccine induces HA inhibition (HAI)-independent protection after heterologous challenge, 
manifested as reduced viral load and fever. On the other hand, we observe increased 
inflammation in the airways and more neutrophil and mononuclear cell infiltration in these 
ferrets when compared with optimally protected animals, i.e., ferrets receiving the same 
vaccine but a homologous challenge. This suggest that HAI-independent immunity 
induced by TIV + CAF01 can reduce viral shedding and systemic disease symptoms, 
but does not reduce local inflammation in the nasal cavity.
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inTrODUcTiOn
Annual influenza epidemics cause illness in up to 30% of the population dependent on age and 
general health status. Worldwide, these annual epidemics are estimated to result in 3–5 million 
cases of severe illness, and about 250,000–500,000 deaths, especially among children, elderly, and 
immune-deprived individuals (http://www.who.int/mediacentre/factsheets/fs211/en/).
Table 1 | Vaccination groups.
Vaccine strain 
compared to 
challenge virus
Vaccine challenge 
virus strain
Without adjuvant With adjuvant
Homologous Trivalent influenza 
split-virion (TIV)2007
TIV2007 + CAF01 A/Brisbane/ 
59/2007
Heterologous TIV2009 TIV2009 + CAF01
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In addition to this, new strains occasionally appear, reflect-
ing mutations and recent re-assortments, causing potentially 
life-threatening pandemics. In the past century, four such pan-
demics have occurred with the most lethal being the Spanish flu 
(1918–1920) killing between 50 and 100 million people, making 
it one of the most deadly disease outbreaks in history (1). For 
the past 20 years, there have been a number of highly pathogenic 
avian influenza strains circulating, which occasionally have 
crossed over to humans, in some cases with fatal outcome as 
recently reported for avian H10N8 (2), H7N9 (3), and H5N6 (4). 
Fortunately, human-to-human transmission of such highly lethal 
strains have not yet been reported, but it may only be a question 
of time before a human adapted variant will appear.
Seasonal flu vaccines primarily work through the induc-
tion of neutralizing antibodies against the principal surface 
antigen hemagglutinin (HA). HA attaches to host cell sialic 
acid receptors thus mediating infection of the cell. Neutralizing 
antibodies directed toward HA therefore reduce infection and 
they can even confer sterilizing immunity. This important role 
of HA-specific antibodies explains why previous pandemics 
have emerged when new HAs have appeared in viruses circu-
lating in the human population. The latest pandemic in 2009 
thus emerged when the circulating swine lineage of H1 HA, 
replaced the circulating human lineage (A/Brisbane/59/2007). 
The emerging H1N1 strain (A/California/04/2009) diverged 
from recent H1 variants with up to 50% in the residues cor-
responding to the antigenic sites of HA and were more closely 
related to the H1 HA strain causing the 1918 pandemic, with as 
little as 20% residue difference (5). To prevent or reduce sever-
ity of future influenza pandemics, it is therefore important to 
develop influenza vaccines, which do not rely so heavily on HA 
neutralization.
Cell-mediated immune responses against highly conserved 
epitopes in proteins such as the matrix proteins (M1 and M2), the 
nucleoprotein, and the polymerase basic proteins (PB1 and PB2) 
have been shown to mediate heterologous and heterosubtypic 
immunity against influenza A (6, 7). Cytotoxic CD8+ T  cells 
are thought to be the primary mediators, but there is mounting 
evidence that also CD4+ T cells can facilitate of heterologous/-
subtypic immunity although the underlying mechanisms are still 
not completely clear (8, 9). The main view is that CD4+ T cells 
provide help to CD8+T cells and B cells to promote viral clearance 
(8, 10). It has, however, been shown that both TH1 and TH17 cells 
transferred into naive mice can protect them against influenza, 
whereas TH2 cells do not play a role (11). This suggests that 
induction of TH1 and TH17 responses to the seasonal trivalent 
influenza split-virion (TIV) vaccine may increase cross-protection 
against heterologous/-heterosubtypic influenza strains and that 
the combination of TIV with the right adjuvant may facilitate this.
Several novel candidate adjuvants in clinical development have 
been assessed within the Advanced Immunization Technologies 
collaborative research program. Among these, the CAF01 adju-
vant was recently shown to generate the strongest T-cell response 
in mice and that this T-cell response was biased toward a mixed 
TH1/TH17 response (12–15). This strong T-cell induction has 
been obtained in both mice, ferrets, pigs, non-human primates, 
calves, and humans (12, 16–21).
In this study, we applied the ferret model to investigate the 
cross-protective efficacy of T cells generated by a heterologous 
TIV vaccine adjuvanted with CAF01. The ferret model has for 
long been the preferred model for testing human influenza 
vaccines, the main reason being that ferrets share host range, 
clinical symptoms, and pathological changes in the respiratory 
tract with humans (22). On the other hand, the ferret model 
is difficult with respect to monitoring immune responses. The 
serum antibody responses to influenza infection and vaccina-
tion are much similar in humans and ferrets, and the methods 
are well established. However, the ferret model has only few 
tools for monitoring innate and adaptive cell-mediated immune 
responses. Vaccine efficacy determined in the ferret model 
therefore has to rely on monitoring of clinical symptoms and 
humoral responses. This complicates the evaluation of the cross 
protectiveness of influenza vaccines in  situations where HA 
neutralization does not play a critical role. We therefore com-
bine the classical clinical monitoring with immunohistological 
examination of the infection site to study the cross-protective 
efficacy of CAF01-adjuvanted TIV.
resUlTs
Our primary goal was to evaluate whether CAF01 could enhance 
the heterologous protection by a TIV vaccine. Thus, we immu-
nized four groups of ferrets with adjuvanted or non-adjuvanted 
suboptimal doses (1/10 human dose) of TIV vaccines containing 
split-virion proteins from Influenza B, H3N2, and H1N1 of either 
the A/Brisbane/59/2007 or the A/California/04/2009 strains 
(designated TIV2007 and TIV2009, respectively) (Table  1). 
Unimmunized ferrets were used as controls.
The ferrets were immunized twice 3 weeks apart. All groups 
including the unimmunized control group were challenged 
intranasally 4 weeks after last immunization, with 105 TCID50 
of the A/Brisbane/59/2007 H1N1 influenza strain. Thus, two 
vaccination groups were challenged with a homologous virus 
and the other two groups were challenged with a heterologous 
virus (Table 1). We also tested the reverse combinations using A/
California/04/2009 as challenge strain. These data are not shown 
since the results were equivalent.
Viral load
The ability of the vaccines to inhibit influenza infection was 
investigated by swabbing the nasal cavity of the ferrets from 
1 to 7  days after challenge and determining the viral load by 
quantitative RT-PCR (Figure 1). The ferrets immunized with the 
FigUre 2 | CAF01 enhances influenza-specific IgG antibody responses 
but not cross-reactive hemagglutination inhibition (HI) responses. Ferrets 
immunized two times with either the seasonal trivalent influenza split-virion 
(TIV)2007 or the seasonal TIV2009 vaccine with or without CAF01 
adjuvant and challenged with the A/Brisbane/59/2007 influenza strain. 
Blood was drawn on 3 days before and 7 days after challenge. (a) IgG 
antibody titers against hemagglutinin (HA) and (b) HI titers against the 
challenge strain. Shown are mean values + SD [n = 8, except for (b): 
heterologous TIV + CAF01 where n = 7]. Statistical analysis: two-way 
ANOVA based on the data shown in each graph. Sidak’s multiple 
comparison test was used to compare the vaccinated with the 
unimmunized group before (white) and after (black) infection. Star symbols 
show statistically significant differences compared to the unimmunized 
group ★p < 0.05, ★★★p < 0.001. Sidak’s multiple comparison test was 
used to compare the intra-group difference before and after infection and 
the hash symbols show statistically significant differences compared to 
before infection #p < 0.05, ##p < 0.01, ###p < 0.001.
FigUre 1 | CAF01 enhances the protection of a split flu vaccine both 
against a homologous and a heterologous challenge. Ferrets immunized 
two times with either the seasonal trivalent influenza split-virion (TIV)2007 
(a) or the seasonal TIV2009 (b) vaccine without adjuvant (▴) or with 
CAF01 adjuvant (▵). Unimmunized controls (⚫). Challenge with the  
A/Brisbane/59/2007 influenza strain. Viral load in nasopharyngeal swab 
samples was determined by quantitative real-time polymerase chain 
reaction. Shown are mean values + SD (n = 8). Statistical analysis: 
repeated-measures two-way ANOVA based on the data shown in each 
graph. Dunnet’s test was used to compare unimmunized to the two other 
groups. Asterisks show statistically significant differences compared to the 
unimmunized group.
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non-adjuvanted vaccines were not protected at the chosen sub-
optimal dose of homologous and heterologous TIV. By contrast, 
the CAF01-adjuvanted TIV vaccine significantly reduced the 
viral load at all time points after homologous challenge. In addi-
tion, the CAF01-adjuvanted vaccine reduced the viral load after 
heterologous challenge at both the two earliest and at the latest 
time points investigated, showing that adjuvanting the TIV with 
CAF01 increases the resistance to challenge with a heterologous 
influenza virus. The reduction in viral load was less pronounced 
after heterologous challenge.
humoral immunity
Protection against influenza is commonly associated with 
antibody-mediated neutralization. The ability of the different 
vaccines to induce IgG antibodies against the dominant surface 
antigen, HA, from the challenge virus was therefore investigated 
(Figure  2A). Only the homologous vaccine adjuvanted with 
CAF01 induced significant TIV-specific IgG titers before chal-
lenge. There was a slight, but insignificant, increase also for the 
ferrets immunized with the heterologous vaccine adjuvanted 
with CAF01, suggesting that some cross-reactive antibodies 
were induced. The regional specificity of these antibodies was 
not investigated but the cross-recognition could be toward 
conserved parts of HA, e.g., the stem region. After challenge, 
the specific IgG antibody response was significantly increased 
above the levels in unvaccinated ferrets only in those groups 
receiving the CAF01-adjuvanted vaccines. In addition, analysis 
of hemagglutination inhibition (HI) titers, which represents the 
correlate of protection used for humans, showed that only the 
CAF01-adjuvanted homologous vaccine was able to induce HI 
titers to the challenge strain before challenge (Figure 2B). None 
of the other vaccines induced HI titers above the level of the 
unimmunized controls at any of the investigated time points 
but all groups had significantly higher HI titers after challenge. 
Thus, the CAF01-adjuvanted heterologous vaccine was unable 
to induce cross-reactive protective HA-specific antibodies 
detectable in either of these analyses, suggesting that the partial 
protection obtained with heterologous vaccination was not 
mediated by HA inhibition (HAI).
FigUre 3 | CAF01 adjuvantation reduces fever after both a homologous 
and a heterologous challenge. Ferrets immunized two times with either the 
seasonal trivalent influenza split-virion (TIV)2007 (a,c) or the seasonal 
TIV2009 (b,D) vaccine without adjuvant (▴) or with CAF01 adjuvant (▵). 
Unimmunized controls (⚫). Challenge with the A/Brisbane/59/2007 influenza 
strain. Changes in relative body temperature (a,b) were determined by 
rectal measurements, where an average of day −1 and 0 were set to 0 and 
the difference was determined as that on the day of measurement minus 
the starting point. Relative weight (c,D) were determined by measurements 
where an average of day −1 and 0 were set to 100% and the difference 
was determined as day of measurement divided by the starting point. 
Shown are mean values + SD (n = 8). Statistical analysis: repeated-
measures two-way ANOVA based on the data shown in each graph. 
Dunnett’s test was used to compare the unimmunized to the two other 
groups. Asterisks show statistically significant differences compared to  
the unimmunized group (p < 0.05).
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clinical symptoms
We also examined if adjuvanting the vaccines could reduce 
clinical symptoms during influenza infection. Thus, the body 
temperature and body weight of the ferrets were monitored 
before and during challenge (Figure 3). Corresponding with 
the reduced viral load, only the CAF01-adjuvanted vac-
cines significantly protected against fever at day 2 after both 
homologous and heterologous challenge (Figures 3A,B). The 
CAF01-adjuvanted vaccine also protected the ferrets against 
weight loss after challenge with the homologous virus but not 
the heterologous vaccine (Figures 3C,D). On the contrary, the 
TIV + CAF01 immunized ferrets after heterologous challenge 
lost weight comparable to unimmunized and TIV immunized 
ferrets and did not gain weight again, as observed for the other 
groups within the 7 days the study lasted. This suggests that the 
TIV-CAF01 vaccine prevents systemic inflammation, whereas 
the weight loss could be explained by local inflammation in 
the airways, causing failure to thrive, and reduced food and 
water intake.
gross Pathology after challenge
Since antibodies could not readily explain the protective effect 
of the CAF01-adjuvanted heterologous vaccine, we assumed 
that it was T-cell mediated based on the known T-cell inducing 
properties of CAF01. However, T-cell responses are notoriously 
difficult to measure in ferrets due to the lack of specific reagents 
of sufficient quality, so we decided to investigate if the observed 
protection was associated with increased influx of lymphocytes 
to the site of infection and/or enhanced local pathology. Thus, 
in a follow-up experiment with all four vaccines, ferrets were 
euthanized and necropsied 4  days after challenge with A/
Brisbane/59/2007, as this time point is commonly associated with 
local pathology in ferret influenza models. Macroscopic lesions 
were not observed in the pharynx or in the lower respiratory tract 
in any of the groups.
histopathology after challenge
As observed from the macroscopic evaluation, histological eva-
luation of the pharyngeal sections revealed no differences between 
the four vaccination groups (data not shown). However, in the 
nasal cavity, there was a significantly lower degree of inflamma-
tion in the homologous TIV + CAF01 group, compared to the 
other vaccination groups (Figures 4 and 5).
Generally, normal ciliated respiratory epithelium was present 
in the majority of each examined section from ferrets in the 
homologous TIV + CAF01 group (Figures 4A,G), while in the 
other groups the nasal mucosa was completely or almost com-
pletely devoid of ciliated epithelial cells as well as goblet cells and 
displayed large regions with hyperplastic epithelium infiltrated 
by moderate to large numbers of neutrophils (Figures 4A,E,F,H; 
described epithelium marked with arrowheads). Regions of 
variable size with flattened epithelium were also present in several 
ferrets.
In the lumen, mild-to-severe amounts of exudate composed 
of neutrophils, cellular debris, and mucus was present in the 
majority of ferrets from the homologous TIV, heterologous TIV, 
and heterologous TIV + CAF01 groups, while either absent or sig-
nificantly reduced in ferrets from the homologous TIV + CAF01 
group (Figures 4B,E–H; exudate marked with stars).
The ventral nasal concha thickness score was statistically sig-
nificant higher in the homologous TIV as well as in the heterolo-
gous TIV and TIV + CAF01 groups compared to the homologous 
TIV + CAF01 group, while no difference was observed between 
the heterologous TIV and TIV + CAF01 groups (Figure 4C). The 
increased thickness of the ventral nasal concha was caused by an 
increased inflammatory cell infiltration of the lamina propria and 
a mild mucosal edema (Figures 4D–H).
The degree of inflammatory cell infiltration in the lamina 
propria was not statistically significantly different between 
the homologous TIV and TIV +  CAF01 groups, whereas the 
infiltration of inflammatory cells was statistically significantly 
higher in the heterologous TIV +  CAF01 group than in the 
heterologous TIV and homologous TIV  +  CAF01 groups 
(Figure  4D). In general, all ferrets that were not protected by 
FigUre 4 | Histopathology in the nasal cavities of ferrets immunized two times with either homologous or heterologous trivalent influenza split-virion (TIV) vaccine 
with or without CAF01 adjuvant and euthanized 4 days after challenge with A/Brisbane/59/2007. (a–D) Scores of % of hematoxylin and eosin (H&E) stained 
sections lacking normal ciliated respiratory epithelium (a), exudate in lumen of the nasal cavity (b), ventral nasal concha thickness (c), and degree of inflammatory 
cell infiltration in lamina propria (D). Dots represent individual values and lines median values, n = 4 (homologous TIV), 6 (homologous TIV + CAF01), and 8 
(heterologous TIV ± CAF01). Histological lesions observed in ferrets vaccinated with homologous TIV + CAF01 was clearly less severe compared to ferrets 
vaccinated with homologous TIV and heterologous TIV ± CAF01. Overall histological lesions observed in ferrets vaccinated with homologous TIV and heterologous 
TIV ± CAF01 were comparable; however, the degree of cellular infiltration in lamina propria was statistically significant higher in heterologous TIV + CAF01 compared 
to both heterologous TIV and homologous TIV + CAF01. (e–h) H&E-stained histological sections of nasal cavities showing unaffected thin nasal concha covered by 
normal ciliated respiratory epithelium from ferret vaccinated with homologous TIV + CAF01 (g) and clearly affected nasal cavities from ferrets vaccinated with 
homologous TIV (e), heterologous TIV (F), and heterologous TIV + CAF01 (h) with exudate in lumen, thickened nasal concha covered by hyperplastic epithelium 
lacking cilia, presence of transmigrating neutrophils and with a mixed inflammatory cell infiltration in lamina propria (most prominent in group TIV2009 + CAF01). 
Stars show exudate, arrowheads show epithelium, and lamina propria is marked with double-headed arrows. Bar = 500 μm. Non-parametric one-way ANOVA 
based on the data shown in each graph. Kruskal–Wallis test by ranks were used to compare the groups. Statistical significant difference is shown by p-value.
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FigUre 5 | Composition of cellular infiltration to the site of infection is influenced by CAF01 adjuvantation. Ferrets immunized two times with either the homologous 
or heterologous trivalent influenza split-virion (TIV) vaccine with or without CAF01 adjuvant and euthanized 4 days after challenge with A/Brisbane/59/2007.  
(a) Score of number of infiltrating neutrophils’ (gray bars) and lymphocytes (black bars) in lamina propria hematoxylin and eosin (H&E)-stained sections, n = 4 
(homologous TIV), 6 (homologous + CAF01), and 8 (heterologous TIV ± CAF01). Bars show mean value + SD. (b–e) Representative histological sections with 
immunohistochemical detection of CD3 showing brown colored CD3(+) T cells in heterologous TIV (b,D) and heterologous TIV + CAF01 (c,e). Bars = 50 μm.  
(F) Score of number CD3(+) T cells and (g) plasma cells (H&E-stained section) in lamina propria. Dots represent individual values and lines median values. Statistical 
analysis: the Mann–Whitney two-tailed U test was applied to compare infiltration of cells between groups. Statistical significant difference is shown by p-value.
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antibodies, i.e., those vaccinated with homologous TIV, het-
erologous TIV, and TIV +  CAF01, experienced an increased 
influx of neutrophils. Furthermore, the cellular infiltration in the 
lamina propria was dominated by neutrophils in ferrets from the 
homologous and heterologous TIV groups (Figure 5A), while 
the cellular infiltration in the heterologous TIV + CAF01 group 
was dominated by substantial infiltration of mononuclear cells 
including lymphocytes (Figure 5A). Thus, vaccination with the 
CAF01-adjuvanted vaccine was associated with infiltration of 
mononuclear cells along with neutrophils, whereas the cell infil-
tration was dominated by neutrophils in those ferrets vaccinated 
with an unadjuvanted TIV vaccine.
Immunohistochemical (IHC) detection of CD3(+) T cells was 
performed on sections from the nasal cavities to investigate if 
heterologous vaccination was associated with a more pronounced 
influx of T cells compared to homologous immunization. A sta-
tistically significantly higher score of the number of infiltrating 
CD3(+) T cells in lamina propria was found in the heterologous 
TIV  +  CAF01 group as compared to both the homologous 
TIV +  CAF01 and the TIV groups (Figure  5F). This is also 
illustrated in the representative slides of CD3 ICH stainings of 
histological sections of the nasal cavity from the two vaccine 
groups receiving heterologous challenge (Figures 5B–E). Finally, 
the number of plasma cells infiltrating into lamina propria after 
infection were scored, and no statistically significant increase was 
observed in the adjuvanted groups (Figure 5G).
DiscUssiOn
It is well established that T cells play an important role in the pro-
tection against influenza infection, especially when HA-specific 
neutralizing antibodies are not available. Several studies have 
thus shown that preexisting T-cell immunity is associated with 
lower virus shedding and less severe illness if antibody-mediated 
neutralization is not possible (23–25).
The efficacy of the seasonal influenza vaccines is very low 
when it comes to infections with influenza strains that are not 
closely matched for HA, because this vaccine predominantly 
induces an antibody response to this antigen and T-cell immu-
nity is not obtained (26). In this study, we therefore combined 
the TIV vaccines with the CAF01 adjuvant which in addition to 
Ab responses is known to elicit a strong T-cell response in both 
mice and humans. Adjuvanting the TIV vaccines with CAF01 
enhanced the protective efficacy, measured as reduced viral load 
and fever, against both homologous and heterologous challenge. 
Despite the absence of detectable cross-reactive HAI antibodies, 
protection after heterologous challenge was not associated with 
an increase in local pathology when comparing to unprotected 
ferrets. Adjuvanting the vaccines changed the cellular recruitment 
to the site of infection from being dominated by neutrophilic 
granulocytes to lymphocytes. Increased infiltration of lympho-
cytes with the adjuvanted vaccines suggests that infection recruits 
lymphocytes that have been induced by vaccination.
This suggest that CAF01 adjuvanted the TIV vaccine increases 
the CMI component of the immune system, which is also sup-
ported by the histological staining of CD3+ cells in the airways 
after intranasal challenge, showing increased infiltration of 
CD3+ T cells. This rapid infiltration of T cells can lead to contain-
ment of the viral infection and faster reduction of viral load in 
the lungs, either by direct killing of infected cells or by mediating 
recruitment of innate immune cells to eliminate the infection. 
This correlates with observations from previous studies showing 
that previous heterologous infection induces a certain extent of 
protective immunity to novel influenza virus subtypes (27–29). 
In addition, Laurie et al. show that multiple infections with dif-
ferent influenza A strains confer better protection than a single 
pre-infection, suggesting that immunity to more conserved B and 
T cell epitopes of the influenza virus play a role for this protection 
(27). This was supported by the observation that primary infec-
tion by influenza strains to which the ferrets were protected by 
vaccination conferred reduced protection in comparison to those 
that were not immune to the primary infection (27, 28). Also, 
Bodewes et al. saw a correlation between the induction of CD3+ 
CD8− T cells coming from primary H3N2 virus infection and 
heterosubtypic protection against H5N1 virus infection (28). This 
role of cross-reactive T cells to mediate partial protection against 
a HA antigenically novel influenza virus has also been shown 
in non-human primates, where animals receiving a primary 
influenza infection had T cells coming into the to the lungs as 
soon as 2 days post-heterologous secondary influenza infection, 
in comparison to 5–7 days in non-primed animals, and that the 
primed animals cleared the secondary infection faster (23).
Despite the observed reduced viral load and fever symptoms 
following the heterologous TIV  +  CAF01 vaccine, we still 
observed weight loss in these animals. This suggest that the heter-
ologous TIV + CAF01 vaccine prevents fever, whereas the weight 
loss could be explained by an increased local inflammation in the 
nasal cavity, as an increased influx of neutrophils and mononu-
clear cells was found in this group, which most likely would lead 
to stuffy and runny noses in those ferrets. Ferrets are obligatory 
nose breathers, and a stuffy nose can lead to respiratory compro-
mise due to the ineffectiveness of mouth breathing, which again 
may lead to reduced food and water intake. We therefore believe 
that the observed weight reduction in this case was a consequence 
of local inflammation in the nasal cavity caused by the infection, 
and enhanced by the vaccine-mediated recruitment of immune 
cells to the airways, which on the other hand reduced the fever.
Overall, this study indicate that the combination of TIV 
vaccines with the TH1/TH17-inducing adjuvant CAF01 leads 
to increased protection against homologous influenza infection 
but also heterologous influenza infection despite absence of 
neutralization via HAI. Although neutralizing Ab responses to 
other antigens than HA can help to increase protection with the 
CAF01-adjuvanted vaccine, the data suggest that CMI induced 
infiltration of mononuclear cells play a major role, when HAI is 
sidelined.
MaTerials anD MeThODs
All animal experiments were approved by the Danish Animal Care 
and Ethics Committee and conducted in accordance with the Danish 
Animal Experimentation Act and the European Convention for the 
Protection of Vertebrate Animals used for Experimental and Other 
Scientific Purposes (permit no. 2012-15-2934-00503). Animals 
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were housed in free-range area with up to 24 animals in each pen. 
The housing was controlled with temperature and humidity and 
animals were on a 12/12-h light cycle. Animals received cat food 
and water ad libitum. Animals were anesthetized with Zoletil for 
cats (90–120  µl dependent on their weight) when sampling and 
measurement of any form were performed and exsanguinated with 
2-ml pentobarbital injection in the heart.
immunization schedule
Outbred, 6–10 months old, female ferrets (Mustela putorius furo, 
n = 4–8) were randomly assigned to groups and vaccinated sub-
cutaneous in the groin two times with 3 weeks in between, with a 
low dose (1/10 human dose) of either the 2007 or 2009 TIV vac-
cine (containing H3N2 and B, plus either A/Brisbane/59/07 or A/
California/07/09 virus antigens). The TIV vaccines were used alone 
or mixed with the CAF01 adjuvant. A control group of unvacci-
nated animals received 250 µl of phosphate-buffered saline (PBS) 
per injection instead of the vaccine. The ferrets were housed in a 
class II isolation facility at the Faculty of Health Sciences, University 
of Copenhagen, with free access to food and water. Before vaccina-
tions, animals were confirmed to be seronegative for circulating 
and applied influenza A (H1N1 and H3N2) and influenza B viruses 
by hemagglutination inhibition assay (HAI) and ELISA.
Eight weeks after vaccination, all animals were inoculated 
intranasally (i.n.) with 105 TCID50 of A/Brisbane/59/2007 H1N1 
produced in eggs. Thus, the challenge was homologous for one 
half of the vaccinated ferrets and heterologous for the other half.
Two repeat studies were performed of which one was termi-
nated 4 days after challenge to sample tissue for histology. During 
challenge, nasal washes and blood samples were taken and tem-
peratures measured daily from day 0 to day 7 post infection (p.i.). 
Nasal washes were performed using a pipette by application of 
1 ml of PBS into the nostrils of each ferret. Nasal wash sample was 
collected and kept at −80°C. Blood samples were taken from the 
cranial vena cava. Temperature was taken by rectal measurement.
clinical symptoms
Since ferrets have a large inter-individual set-point for “normal” 
temperature we measured the relative change in body tempera-
ture. The set point was determined as the average of the two meas-
urements before infection in individual animals and the indicated 
changes were calculated as that on the day of measurement minus 
the set-point value.
Weight was measured during anesthesia. The starting point 
was determined as the average of the two measurements before 
infection in individual animals and this value was set to 100%. 
The indicated changes were calculated as that on the day of 
measurement divided by the starting value.
igg antibodies
Detection of anti-HA antibodies in the sera from ferrets was 
performed by ELISA. In brief, 96-well MaxiSorp plates (Nunc, 
Denmark) were coated with 0.5  mg/ml of HA from either 
A/California/04/2009 in 15 mM Na2CO3, 35 mM NaHCO3 (pH 
9.7), overnight at 4°C. The plates were blocked in PBS containing 
2% (w/v) skimmed milk, and then the sera were added in two-
fold serial dilutions. On all plates an in-house positive reference 
serum pool was added in twofold dilutions. Specific antibodies 
were detected following incubation with rabbit anti-mouse IgG 
conjugated to horseradish peroxidase (HRP) (Zymed/Invitrogen) 
by addition of the TMB Plus Ready-to-use substrate (Kem-En-
Tec, Taastrup, Denmark). The reaction was stopped at the optimal 
color development with 0.2 M H2SO4, and absorbance (OD) was 
read at 450  nm with wavelength correction at 620  nm to cor-
rect for optical imperfections including air bubbles in the plates. 
The antibody used for detection was HRP-conjugated anti IgG 
(Invitrogen, Frederick, MD, USA).
The relative concentration of HA-specific IgG was calculated 
based on the positive reference standard curve (top dilution set to 
100 AU/ml). The corrected OD values were log–log transformed 
and the standard curve fitted manually to contain as many points 
as possible on a straight line (r > 0.99 or n ≥ 4). Only OD values 
for the dilutions of a sample within this linear interval of the 
reference were used to calculate the antibody titer of that sample.
Slope (b), intercept (a), and correlation (r) were calculated 
for the best fitted standard curve according to the method of 
least squares. According to the formula: y =  bx +  a (where 
y = OD and x = dilution), the relative dilution of each OD values 
for the samples can be calculated according to this formula: 
Anti-log[(((ODsample  −  ODbackground))  −  Standard-intercept(a))/
Standard-slope(b)] = dilution.
The absolute concentration (titer) is then calculated by adjust-
ing the calculated dilution with the plate dilution. This adjusted 
dilution is then divided into the concentration of the standard.
hemagglutination inhibition
Blood was drawn from animals 3  days before and 7  days after 
infection with influenza and serum was prepared and stored at 
−20°C until use. HI titers were determined by endpoint titra-
tion. In 96-well round-bottom plates, serum was diluted twofold 
in 50  µl PBS and incubated with 50  µl 4 HA  U influenza A/
Brisbane/59/2007 for 30 min. After incubation, 50 µl 0.5% chicken 
RBC was added and incubated for further 60 min before hemag-
glutination was scored as the well with the most diluted serum 
that can prevent hemagglutination. Controls included were serum 
control (50 µl serum + 50 µl PBS + 50 µl RBC), virus control (50 µl 
virus + 50 µl PBS + 50 µl RBC), and erythrocyte control (100 µl 
PBS + 50 µl RBC). All samples were analyzed in duplicate wells.
Quantitative real-time Polymerase  
chain reaction (qrT-Pcr)
Viral loads in nasopharyngeal swab samples collected at days 1, 2, 
3, 4, and 7 were determined using qRT-PCR. The influenza M gene 
was absolutely quantified while the housekeeping gene, murine 
glyceraldehyde-3-phosphate dehydrogenase (mGAPDH), was 
included in the amplifications to address inter-PCR variations. 
The reliability of this assay was previously validated through cor-
relation with infective titers as determined by plaque assay.
The protocol has previously been described in Andersson 
et al. (30). In brief, the Brilliant II qRT-PCR, 1-step kit (Agilent 
Technologies) was used. The following was added to each well: 
100 ng purified RNA, 12.5 µl master mix, 0.5 µl of each primer 
(10  µM), 0.5  µl mGAPDH probe (10  µM), 0.75  µl M probe 
Table 2 | Primers and probes used for quantitative real-time polymerase chain 
reaction.
Primers and probes sequence (5′–3′)
M forward primer AGA TGA GTC TTC TAA CCG AGG TCG
M reverse primer TGC AAA AAC ATC TTC AAG TCT CTG
M probe FAM-TCA GGC CCC CTC AAA GCC GA-BHQ-1
mGAPDH forward primer CAA TGT GTC CGT CGT GGA
mGAPDH reverse primer GAT GCC TGC TTC ACC ACC
mGAPDH probe HEX-CGC CTG GAG AAA CCT GCC AAG 
TAT-BHQ-1
Primers and probes were synthesized at TAQ Copenhagen A/S.
FAM, carboxyfluorescein; BHQ-1, BlackHoleQuencher-1; HEX, hexachlorofluorescein; 
mGAPDH, murine glyceraldehyde-3-phosphate dehydrogenase.
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(10 µM), 0.375 µl (1:500) reference dye, and 1 µl RT/RNase block 
enzyme mixture diluted in Milli-Q water to a total volume of 
25 µl. See Table 2 for primers and probes used.
Samples were run on an Mx3000P Real-time QPCR instru-
ment (Agilent Technologies) according to the following settings: 
30 min/50°C, 10 min/95°C followed by 40 cycles of 30 s/95°C, 
1 min/58°C, and 30 s/72°C. All samples were run in triplicates 
and standard curves in duplicates. The copy number was deter-
mined with an optical density read out. The obtained results were 
analyzed using the Stratagene MxPro software.
gross Pathology and histopathology
Four days after challenge, all ferrets were euthanized and necrop-
sied. The ferrets heads and a segment of the pharynx were fixed 
in 10% neutral-buffered formalin. Following decalcification of 
the heads by ethylenediaminetetraacetic acid (EDTA + NaOH), 
a segment of the nasal cavity including the nasal concha was 
obtained at the level of the upper canine tooth. The tissues were 
routinely processed, embedded in paraffin, and sectioned. From 
each ferret, one section of the pharynx and one section of nasal 
cavity were stained with hematoxylin and eosin (H&E). In addi-
tion, one section of the nasal cavity was used for IHC detection 
of CD3. All processing and staining of the section was done at 
Nordic Biosite. All sections were examined by light microscopy 
by a pathologist blinded to the groups. In H&E-stained section 
of the nasal cavities, the following were scored: thickness of 
ventral nasal concha (score 1–4; 1, normal; 2, slightly increased; 
3, moderately increased; 4, severely increased), lack of normal 
ciliated respiratory epithelium (score 1–4; 1, lacking in ≥0–25% 
of the section; 2, lacking in >25 to ≤50% of the section; 3, lack-
ing in >50 to <90% of the section; 4, lacking in 90–100% of the 
section), the degree of inflammatory cell infiltration in lamina 
propria and the amount of exudate in the nasal cavity (score 
0–4; 0, absent; 1, minimal; 2, mild; 3, moderate; 4, severe), the 
number of lymphocytes, neutrophils, and plasma cells (score 
0–3; 0, absent; 1, few; 2 moderate; 3, many).
Immunohistochemical staining was performed by incubating 
tissue sections with monoclonal antibodies against CD3, followed 
by incubation with isotype-specific antibodies (DAKO). In IHC 
stained sections, the number of CD3(+) T-cells were scored 
(score 0–3; 0, absent; 1, few; 2, moderate; 3, many).
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This study was carried out in accordance with the recommenda-
tions of “Danish Animal Experimentation Act and the European 
Convention for the Protection of Vertebrate Animals used for 
Experimental and Other Scientific Purposes.” The protocol was 
approved by the “Danish Animal Care and Ethics Committee” 
(permit no. 2012-15-2934-00503).
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